These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 28247849)

  • 1. Meta-Analysis of the Usefulness of Plasma Galectin-3 to Predict the Risk of Mortality in Patients With Heart Failure and in the General Population.
    Imran TF; Shin HJ; Mathenge N; Wang F; Kim B; Joseph J; Gaziano JM; Djoussé L
    Am J Cardiol; 2017 Jan; 119(1):57-64. PubMed ID: 28247849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3.
    Bayes-Genis A; de Antonio M; Vila J; Peñafiel J; Galán A; Barallat J; Zamora E; Urrutia A; Lupón J
    J Am Coll Cardiol; 2014 Jan; 63(2):158-66. PubMed ID: 24076531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The fibrosis marker galectin-3 and outcome in the general population.
    de Boer RA; van Veldhuisen DJ; Gansevoort RT; Muller Kobold AC; van Gilst WH; Hillege HL; Bakker SJ; van der Harst P
    J Intern Med; 2012 Jul; 272(1):55-64. PubMed ID: 22026577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: The Rancho Bernardo Study.
    Daniels LB; Clopton P; Laughlin GA; Maisel AS; Barrett-Connor E
    Am Heart J; 2014 May; 167(5):674-82.e1. PubMed ID: 24766977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of diabetes on the predictive value of heart failure biomarkers.
    Alonso N; Lupón J; Barallat J; de Antonio M; Domingo M; Zamora E; Moliner P; Galán A; Santesmases J; Pastor C; Mauricio D; Bayes-Genis A
    Cardiovasc Diabetol; 2016 Nov; 15(1):151. PubMed ID: 27809845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of galectin-3 as a prognostic biomarker in heart failure: where do we stand?
    Srivatsan V; George M; Shanmugam E
    Eur J Prev Cardiol; 2015 Sep; 22(9):1096-110. PubMed ID: 25268020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of galectin-3 on admission in Chinese patients with heart failure: a prospective observational study.
    Wang H; Chen Q; Li Y; Jing X; Liang T; Yang J
    Acta Cardiol; 2017 Apr; 72(2):188-195. PubMed ID: 28597803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serial galectin-3 and future cardiovascular disease in the general population.
    van der Velde AR; Meijers WC; Ho JE; Brouwers FP; Rienstra M; Bakker SJ; Muller Kobold AC; van Veldhuisen DJ; van Gilst WH; van der Harst P; de Boer RA
    Heart; 2016 Jul; 102(14):1134-41. PubMed ID: 27084804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Value of Serial Galectin-3 Measurements in Patients With Acute Heart Failure.
    van Vark LC; Lesman-Leegte I; Baart SJ; Postmus D; Pinto YM; de Boer RA; Asselbergs FW; Wajon EMCJ; Orsel JG; Boersma E; Hillege HL; Akkerhuis KM;
    J Am Heart Assoc; 2017 Nov; 6(12):. PubMed ID: 29187387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Galectin-3 levels and long-term all-cause mortality and hospitalization in heart failure patients: a meta-analysis.
    Cheng W; Maciej R; Thiele H; Büttner P
    ESC Heart Fail; 2024 Oct; 11(5):2566-2577. PubMed ID: 38698741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The utility of galectin-3 for predicting cause-specific death in hospitalized patients with heart failure.
    Zhang Y; Zhang R; An T; Huang Y; Guo X; Yin S; Wang Y; Ji S; Lv R; Zhang J; Maisel A
    J Card Fail; 2015 Jan; 21(1):51-9. PubMed ID: 25463412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH.
    van der Velde AR; Gullestad L; Ueland T; Aukrust P; Guo Y; Adourian A; Muntendam P; van Veldhuisen DJ; de Boer RA
    Circ Heart Fail; 2013 Mar; 6(2):219-26. PubMed ID: 23395934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community.
    Ho JE; Liu C; Lyass A; Courchesne P; Pencina MJ; Vasan RS; Larson MG; Levy D
    J Am Coll Cardiol; 2012 Oct; 60(14):1249-56. PubMed ID: 22939561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal function largely influences Galectin-3 prognostic value in heart failure.
    Zamora E; Lupón J; de Antonio M; Galán A; Domingo M; Urrutia A; Troya M; Bayes-Genis A
    Int J Cardiol; 2014 Nov; 177(1):171-7. PubMed ID: 25499371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure.
    van Kimmenade RR; Januzzi JL; Ellinor PT; Sharma UC; Bakker JA; Low AF; Martinez A; Crijns HJ; MacRae CA; Menheere PP; Pinto YM
    J Am Coll Cardiol; 2006 Sep; 48(6):1217-24. PubMed ID: 16979009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers and low risk in heart failure. Data from COACH and TRIUMPH.
    Meijers WC; de Boer RA; van Veldhuisen DJ; Jaarsma T; Hillege HL; Maisel AS; Di Somma S; Voors AA; Peacock WF
    Eur J Heart Fail; 2015 Dec; 17(12):1271-82. PubMed ID: 26466857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of a combination of monocyte chemoattractant protein-1, galectin-3, and N-terminal probrain natriuretic peptide to predict cardiovascular events in patients with coronary artery disease.
    Tuñón J; Blanco-Colio L; Cristóbal C; Tarín N; Higueras J; Huelmos A; Alonso J; Egido J; Asensio D; Lorenzo Ó; Mahíllo-Fernández I; Rodríguez-Artalejo F; Farré J; Martín-Ventura JL; López-Bescós L
    Am J Cardiol; 2014 Feb; 113(3):434-40. PubMed ID: 24295549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of galectin-3 for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohort.
    Jagodzinski A; Havulinna AS; Appelbaum S; Zeller T; Jousilahti P; Skytte-Johanssen S; Hughes MF; Blankenberg S; Salomaa V
    Int J Cardiol; 2015 Aug; 192():33-9. PubMed ID: 25985013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
    Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
    Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study.
    Lok DJ; Van Der Meer P; de la Porte PW; Lipsic E; Van Wijngaarden J; Hillege HL; van Veldhuisen DJ
    Clin Res Cardiol; 2010 May; 99(5):323-8. PubMed ID: 20130888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.